Literature DB >> 15761114

UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: I. Identification of polymorphisms in the 5'-regulatory and exon 1 regions, and association with human liver UGT1A6 gene expression and glucuronidation.

Soundararajan Krishnaswamy1, Qin Hao, Abdul Al-Rohaimi, Leah M Hesse, Lisa L von Moltke, David J Greenblatt, Michael H Court.   

Abstract

UDP glucuronosyltransferase (UGT) 1A6 is a major isoform in human liver that glucuronidates numerous drugs, toxins, and endogenous substrates with high interindividual variability. The molecular basis for this variability remains unknown, although it likely involves genetic and environmental factors. Phenotype-genotype studies were conducted using a well characterized human liver bank (n = 54) and serotonin glucuronidation as a UGT1A6-specific phenotype marker. A positive moderate-to-heavy alcohol use history (>14 drinks per week) was the only demographic factor examined that correlated with phenotype and was associated with 2-fold higher serotonin glucuronidation (p < 0.001), UGT1A6 protein content (p = 0.004), and UGT1A6 mRNA content (p = 0.025). UGT1A6 gene resequencing identified three nonsynonymous polymorphisms (S7A, T181A, and R184S) in exon 1 and eight novel polymorphisms in the 5'-regulatory region (to -2052 base pairs). S7A was in complete linkage disequilibrium with three 5'-regulatory region polymorphisms (-1710c-->g, -1310del5, and -652g-->a). Initial univariate analyses did not identify any significant phenotype-genotype associations. However, in livers without substantial alcohol exposure, 50% lower UGT1A6 mRNA levels (p = 0.026) were found in carriers of the linked S7A-enhancer polymorphisms compared with noncarriers but without significant effect on UGT1A6 protein content or glucuronidation activities. Three major haplotypes, including (*)1A (reference), (*)1B (-1535g-->a and -427g-->c), and (*)2 (-1710c-->g, -1310del5, -652g-->a, S7A, T181A, and R184S), were identified, accounting for 90% of alleles. No association of haplotype with any of the phenotype measures could be discerned. In conclusion, although the identified UGT1A6 polymorphisms did not explain the observed glucuronidation variability, there does seem to be a significant role for environmental factors associated with alcohol consumption.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15761114     DOI: 10.1124/jpet.104.081950

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  16 in total

1.  Quantification of human uridine-diphosphate glucuronosyl transferase 1A isoforms in liver, intestine, and kidney using nanobore liquid chromatography-tandem mass spectrometry.

Authors:  David E Harbourt; John K Fallon; Shinya Ito; Takashi Baba; Joseph K Ritter; Gary L Glish; Philip C Smith
Journal:  Anal Chem       Date:  2011-12-05       Impact factor: 6.986

2.  UGT1A6 and UGT2B15 polymorphisms and acetaminophen conjugation in response to a randomized, controlled diet of select fruits and vegetables.

Authors:  Sandi L Navarro; Yu Chen; Lin Li; Shuying S Li; Jyh-Lurn Chang; Yvonne Schwarz; Irena B King; John D Potter; Jeannette Bigler; Johanna W Lampe
Journal:  Drug Metab Dispos       Date:  2011-06-10       Impact factor: 3.922

3.  Genetic variation in UGT genes modify the associations of NSAIDs with risk of colorectal cancer: colon cancer family registry.

Authors:  Dominique Scherer; Lisel M Koepl; Elizabeth M Poole; Yesilda Balavarca; Liren Xiao; John A Baron; Li Hsu; Anna E Coghill; Peter T Campbell; Sarah E Kleinstein; Jane C Figueiredo; Johanna W Lampe; Katharina Buck; John D Potter; Richard J Kulmacz; Mark A Jenkins; John L Hopper; Aung K Win; Polly A Newcomb; Cornelia M Ulrich; Karen W Makar
Journal:  Genes Chromosomes Cancer       Date:  2014-03-28       Impact factor: 5.006

4.  Novel polymorphic human UDP-glucuronosyltransferase 2A3: cloning, functional characterization of enzyme variants, comparative tissue expression, and gene induction.

Authors:  Michael H Court; Suwagmani Hazarika; Soundararajan Krishnaswamy; Moshe Finel; J Andrew Williams
Journal:  Mol Pharmacol       Date:  2008-06-03       Impact factor: 4.436

5.  The UDP-glucuronosyltransferase (UGT) 1A polymorphism c.2042C>G (rs8330) is associated with increased human liver acetaminophen glucuronidation, increased UGT1A exon 5a/5b splice variant mRNA ratio, and decreased risk of unintentional acetaminophen-induced acute liver failure.

Authors:  Michael H Court; Marina Freytsis; Xueding Wang; Inga Peter; Chantal Guillemette; Suwagmani Hazarika; Su X Duan; David J Greenblatt; William M Lee
Journal:  J Pharmacol Exp Ther       Date:  2013-02-13       Impact factor: 4.030

6.  Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system.

Authors:  Michael H Court
Journal:  Drug Metab Rev       Date:  2010-02       Impact factor: 4.518

7.  UGT1A6 genotype-related pharmacokinetics of deferiprone (L1) in healthy volunteers.

Authors:  Lie Michael George Limenta; Totsapol Jirasomprasert; Jeeranut Tankanitlert; Saovaros Svasti; Prapin Wilairat; Udom Chantharaksri; Suthat Fucharoen; Noppawan Phumala Morales
Journal:  Br J Clin Pharmacol       Date:  2008-03-03       Impact factor: 4.335

8.  Effect of the beta-glucuronidase inhibitor saccharolactone on glucuronidation by human tissue microsomes and recombinant UDP-glucuronosyltransferases.

Authors:  Lauren Oleson; Michael H Court
Journal:  J Pharm Pharmacol       Date:  2008-09       Impact factor: 3.765

9.  The effect of UGT1A and UGT2B polymorphisms on colorectal cancer risk: haplotype associations and gene–environment interactions.

Authors:  Andrea Y Angstadt; Terryl J Hartman; Samuel M Lesko; Joshua E Muscat; Junjia Zhu; Carla J Gallagher; Philip Lazarus
Journal:  Genes Chromosomes Cancer       Date:  2014-06       Impact factor: 5.006

10.  Candidate gene polymorphisms in patients with acetaminophen-induced acute liver failure.

Authors:  Michael H Court; Inga Peter; Suwagmani Hazarika; Magdalini Vasiadi; David J Greenblatt; William M Lee
Journal:  Drug Metab Dispos       Date:  2013-10-08       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.